Literature DB >> 8204507

HIV protease as an inhibitor target for the treatment of AIDS.

P L Darke1, J R Huff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8204507     DOI： 10.1016/s1054-3589(08)60438-x

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN： 1054-3589


× No keyword cloud information.
  11 in total

1.  Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease.

Authors:  C D Rosin; R K Belew; G M Morris; A J Olson; D S Goodsell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

2.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors:  L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

3.  Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir.

Authors:  Arun K Ghosh; Dongwoo Shin; Packiarajan Mathivanan
Journal:  Chem Commun (Camb)       Date:  1999       Impact factor: 6.222

4.  Syntheses of FDA Approved HIV Protease Inhibitors.

Authors:  Arun K Ghosh; Geoffrey Bilcer; Gary Schiltz
Journal:  Synthesis (Stuttg)       Date:  2001       Impact factor: 3.157

5.  Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  D Lamarre; G Croteau; E Wardrop; L Bourgon; D Thibeault; C Clouette; M Vaillancourt; E Cohen; C Pargellis; C Yoakim; P C Anderson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Understanding HIV-1 protease autoprocessing for novel therapeutic development.

Authors:  Liangqun Huang; Chaoping Chen
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

7.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Authors:  Y M Zhang; H Imamichi; T Imamichi; H C Lane; J Falloon; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 9.  HIV protease inhibitors in gut barrier dysfunction and liver injury.

Authors:  Xudong Wu; Yunzhou Li; Kesong Peng; Huiping Zhou
Journal:  Curr Opin Pharmacol       Date:  2014-08-06       Impact factor: 5.547

10.  SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety.

Authors:  A Billich; G Fricker; I Müller; P Donatsch; P Ettmayer; H Gstach; P Lehr; P Peichl; D Scholz; B Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.